Kercheville Advisors LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Kercheville Advisors LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 19,450 shares of the company’s stock, valued at approximately $470,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. GAMMA Investing LLC increased its stake in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the period. Quest Partners LLC increased its stake in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Hims & Hers Health by 115.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after acquiring an additional 2,442 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 0.6 %

HIMS opened at $42.12 on Thursday. The firm’s fifty day simple moving average is $29.82 and its two-hundred day simple moving average is $23.00. The company has a market cap of $9.20 billion, a price-to-earnings ratio of 95.72 and a beta of 1.35. Hims & Hers Health, Inc. has a 52-week low of $8.58 and a 52-week high of $44.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the firm posted ($0.04) earnings per share. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $38.92, for a total transaction of $450,732.52. Following the transaction, the chief financial officer now directly owns 112,933 shares of the company’s stock, valued at $4,395,352.36. The trade was a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the transaction, the insider now directly owns 184,947 shares in the company, valued at $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,167,913 shares of company stock valued at $34,303,787. Corporate insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HIMS. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Needham & Company LLC raised their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Morgan Stanley assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.